MX2024004107A - Sistemas y metodos para modelar y controlar el ph. - Google Patents

Sistemas y metodos para modelar y controlar el ph.

Info

Publication number
MX2024004107A
MX2024004107A MX2024004107A MX2024004107A MX2024004107A MX 2024004107 A MX2024004107 A MX 2024004107A MX 2024004107 A MX2024004107 A MX 2024004107A MX 2024004107 A MX2024004107 A MX 2024004107A MX 2024004107 A MX2024004107 A MX 2024004107A
Authority
MX
Mexico
Prior art keywords
systems
methods
control
titrant
modeling
Prior art date
Application number
MX2024004107A
Other languages
English (en)
Inventor
Ross Browne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024004107A publication Critical patent/MX2024004107A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/30—Electrodes, e.g. test electrodes; Half-cells
    • G01N27/302—Electrodes, e.g. test electrodes; Half-cells pH sensitive, e.g. quinhydron, antimony or hydrogen electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/4163—Systems checking the operation of, or calibrating, the measuring apparatus
    • G01N27/4165—Systems checking the operation of, or calibrating, the measuring apparatus for pH meters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/4166—Systems measuring a particular property of an electrolyte
    • G01N27/4167—Systems measuring a particular property of an electrolyte pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/16—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using titration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/12—Circuits of general importance; Signal processing
    • G01N2201/127—Calibration; base line adjustment; drift compensation
    • G01N2201/12746—Calibration values determination

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Electrochemistry (AREA)
  • Plasma & Fusion (AREA)
  • Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación se refiere a sistemas y métodos para controlar el pH de una muestra, que comprende medir un pH inicial, agregar una cantidad de titulador y medir un segundo pH, y utilizar un modelado no dimensional para normalizar el titulador y determinar la cantidad de titulador necesaria para alcanzar un pH final. Los sistemas y métodos pueden usarse para controlar el pH durante la inactivación viral o titulación de muestras de proteínas.
MX2024004107A 2021-10-07 2022-10-06 Sistemas y metodos para modelar y controlar el ph. MX2024004107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163253281P 2021-10-07 2021-10-07
PCT/US2022/045902 WO2023059800A2 (en) 2021-10-07 2022-10-06 Systems and methods of ph modeling and control

Publications (1)

Publication Number Publication Date
MX2024004107A true MX2024004107A (es) 2024-04-19

Family

ID=84364085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004107A MX2024004107A (es) 2021-10-07 2022-10-06 Sistemas y metodos para modelar y controlar el ph.

Country Status (10)

Country Link
US (1) US20230116199A1 (es)
EP (1) EP4413364A2 (es)
KR (1) KR20240090311A (es)
CN (1) CN118076894A (es)
AU (1) AU2022360838A1 (es)
CA (1) CA3230984A1 (es)
IL (1) IL311245A (es)
MX (1) MX2024004107A (es)
TW (1) TW202323817A (es)
WO (1) WO2023059800A2 (es)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0082974B1 (en) 1981-12-24 1986-05-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US4940551A (en) * 1989-05-19 1990-07-10 Riggs James B Method for pH control
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
WO2004104186A1 (en) 2003-05-15 2004-12-02 Wyeth Restricted glucose feed for animal cell culture
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
NZ726602A (en) 2014-05-05 2024-05-31 Regeneron Pharmaceuticals Inc Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
EP3426683A1 (en) * 2016-03-11 2019-01-16 Boehringer Ingelheim International GmbH Methods for continuously inactivating a virus during manufacture of a protein
MX2022001166A (es) * 2019-08-01 2022-02-23 Regeneron Pharma Metodo para inactivacion viral.

Also Published As

Publication number Publication date
AU2022360838A1 (en) 2024-03-28
WO2023059800A3 (en) 2023-06-01
EP4413364A2 (en) 2024-08-14
KR20240090311A (ko) 2024-06-21
CA3230984A1 (en) 2023-04-13
CN118076894A (zh) 2024-05-24
US20230116199A1 (en) 2023-04-13
WO2023059800A2 (en) 2023-04-13
IL311245A (en) 2024-05-01
TW202323817A (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
EP3878862A3 (en) Anti-coronavirus antibodies and methods of use
PH12020500103A1 (en) Use of cas protein, method for detecting target nucleic acid molecule, and kit
ATE416376T1 (de) Analysegeräte, biosensoren und verfahren
AU2018218386A8 (en) Method for producing HSL protein having improved catalytic activity for 2-oxoglutaric acid-dependently oxidizing 4-HPPD inhibitor
BR112015023012A2 (pt) titulador automático
BR112017026915A2 (pt) ?processador e codificador de áudio e método para processar e gerar sinal de áudio?
SG10201807736SA (en) Composition and method for stabilizing nucleic acids in biological samples
ATE479780T1 (de) Qpcr unter verwendung eines ionen-sensitiven feldeffekt-transistors zur ph-messung
MX2020012329A (es) Dispositivo, sistema y metodo para medicion electrica directa de actividad enzimatica.
DE60313652D1 (de) Verfahren und gerät zur kontrolle der umwandlung von programm-kodes
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
CA3156351A1 (en) ANALYTE MEASUREMENT SYSTEM
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
MX2021008923A (es) Aparato, sistema y metodo para determinar uno o mas parametros de un error refractivo de un ojo examinado.
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
WO2020064997A8 (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
MX2024004107A (es) Sistemas y metodos para modelar y controlar el ph.
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
EP4107653C0 (en) METHOD, SYSTEM AND COMPUTER PROGRAMS FOR TRACEABILITY OF LIVING SPECIMENS
MX2024004108A (es) Calibracion y correccion de medidor de ph.
ATE429503T1 (de) Kontrolle der genexpression in plastiden
ATE470147T1 (de) Verfahren und mittel zur bestimmung von gesamthärte
EP4269612A4 (en) NUCLEIC ACID AMPLIFICATION METHOD, PRIMER SET, PROBE AND KIT FOR NUCLEIC ACID AMPLIFICATION METHOD
EP3995586A4 (en) GLYCOSYL PROTEIN ASSAY REAGENT CONTAINING FERROCYANIDE REDOX POTENTIAL-INCREASING PROTEASE STABILIZER, METHOD FOR GLYCOSYL PROTEIN ASSAY, METHOD FOR PRESERVING GLYCOSYL PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING PROTEIN GLYCOSYL ASSAY REAGENT YLEE
EP3665472A4 (en) METHOD AND SYSTEM FOR DETERMINING THE CONCENTRATION OF A CHEMICAL SPECIES USING NMR